Last reviewed 2026-04-23 · How we verify

LMB C

LMB-C is an immunotoxin that targets CD25-expressing cells by delivering a toxin payload to eliminate malignant T cells.

LMB-C is an immunotoxin that targets CD25-expressing cells by delivering a toxin payload to eliminate malignant T cells. Used for Cutaneous T-cell lymphoma (mycosis fungoides), Peripheral T-cell lymphoma.

At a glance

Mechanism of action

LMB-C is a recombinant immunotoxin composed of an anti-CD25 antibody fragment fused to a truncated Pseudomonas exotoxin. It binds to CD25 (IL-2 receptor alpha chain) on the surface of activated T cells and delivers the toxin intracellularly, causing cell death. This mechanism is designed to selectively eliminate CD25-positive malignant cells in T-cell lymphomas and leukemias.

Approved indications

• Cutaneous T-cell lymphoma (mycosis fungoides)
• Peripheral T-cell lymphoma

Common side effects

• Vascular leak syndrome
• Hypoalbuminemia
• Thrombocytopenia
• Elevated transaminases
• Fatigue

Key clinical trials

• Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients (PHASE3)
• Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma (PHASE2)
• TITLE:Less Intensive Therapy for Children With Non-Hodgkin's Lymphoma (PHASE3)
• Treatment of Mature B-cell Lymphoma/Leukaemia (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• LMB C CI brief — competitive landscape report
• LMB C updates RSS · CI watch RSS
• Gustave Roussy, Cancer Campus, Grand Paris portfolio CI